Judge dismisses AstraZeneca's lawsuit against Medicare's drug price negotiation program.

Judge dismisses AstraZeneca's lawsuit challenging Medicare's drug price negotiation program, citing lack of legal standing. The pharmaceutical company failed to identify any property interest protected by the constitution that is put in jeopardy by the program. This represents the third district court to side with the administration in cases challenging the President's prescription drug law, and is the first case to be fully decided on the merits.